260 million! Hesco transferred its interest in a new drug for prostate cancer to Haitron Pharmaceuticals.

On September 7, Haisco announced that its subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. signed a Patent Implementation License Agreement and Related Agreement Lifting Agreement with Chengdu Haitron Pharmaceutical Co., Ltd. on September 4, and that Haisco will grant exclusive license to HC-1119 and its patented products and patent methods for various pharmaceutical preparations as active ingredients. Rights, new technological achievements arising from patented products in China and their co-ownership of supporting property rights, and all rights to clinical trials, drug registration certificates and new drug certificates, research and development rights, production rights, sales rights, commercialization rights, trademarks (generic names) and other intellectual property rights are transferred to Haitron Pharmaceuticals, with a total transfer value of 260 million yuan, to be paid in three installments.
the agreement, the first payment of 50 million yuan, the second payment of 60 million yuan, the third payment of 150 million yuan.
to avoid doubt, Party B is not required to pay a third instalment if it fails to successfully list.
HC-1119 series of Hesco equity enterprise Haitron Pharmaceuticals independently developed prostate cancer drugs, belongs to the androgen-affected antagonists, is energizer products, can be in the target tissue with androgen-like products, blocking the binding of metoxypertin and androgen-liker, inhibit the target tissue intake of testosterone, thereby playing an anti-androgen and inhibit the growth of prostate cancer cells.
is currently conducting a global multi-center Phase III clinical trial for mCRPC patients, and the product has been granted nearly 30 patents in China, the United States, Japan, Europe and other countries and regions.
HC-1119 has launched a global multi-center Phase III clinical trial in 2018 and plans to apply for global listing in 2022, Hesco said on an interactive platform, HC-1119 if successfully listed in China, its future market space is expected to exceed 2 billion yuan.
in 2016, Sichuan Haisco used its own funds of 33.454 million yuan to invest in Chengdu Haitron Pharmaceutical Co., Ltd., and obtained exclusive license for HC-1119 and various pharmaceutical preparations with active ingredients in China.
development expenditure for the HC-1119 project at the end of the first half of 2020 exceeded 90.45 million yuan.
At the beginning of this year, Haitron Pharmaceuticals raised $32 million to complete the contract, under the lead of Tongde Capital and Fosun Pharma, Haitron Pharmaceuticals B-round and B-plus round raised a total amount of $72 million.
three years ago, Haitron Pharmaceuticals' round A financing officially came from Hesco.
June 15 this year, Hesco announced that it intends to use its own funds of about $878.6 million to buy a 7.5096 percent stake in Chengdu Haitron Pharmaceuticals, owned by Hong Kong-based Haitron Pharmaceuticals.
Windhill Source: Medical Rubik's Cube !-- end of content display -- !-- to determine whether the login is over.